Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.

@article{Sato2012VorinostatAB,
  title={Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.},
  author={Akinori Sato and Takako Asano and Keiichi Ito and Tomohiko Asano},
  journal={The Journal of urology},
  year={2012},
  volume={188 6},
  pages={2410-8}
}
PURPOSE Protein ubiquitination is a novel strategy used to treat malignancies. We investigated whether the histone deacetylase inhibitor vorinostat (Cayman Chemical, Ann Arbor, Michigan) and the proteasome inhibitor bortezomib (LC Laboratories, Woburn, Massachusetts) would synergistically cause the accumulation of ubiquitinated proteins in prostate cancer cells. MATERIALS AND METHODS LNCaP, PC-3 and DU 145 cells (ATCC™) were treated with vorinostat and/or bortezomib. Cell viability and… CONTINUE READING